Mast Therapeutics Inc (NYSEMKT:MSTX) may not have had a happy ending to the year just gone by, but it bid its farewell by announcing the start of investigator-sponsored Phase 2 study of AIR001. Vepoloxamer, the company’s cell disease drug trial crashed in the month of September 2016, which shook its respectable stature. Since then, Mast is back into what can be said reputation management strategy.
Kicking off new Investigator-Sponsored Phase 2 Study Of AIR001
First patient into the fresh study has been enrolled, according to the latest press release of Mast. AIR001 is the lead product of this company and it is betting high on this one with a profitable treatment for HFpEF or heart failure with preserved ejection fraction.
The company’s INABLE-TRAINING or Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training is meant to be undertaken in this HFpEF study. The new study will evaluate the feasibility of AIR001.
Study to enrol 68 patients
This new study will begin with 68 patients, all of whom will undergo a cardiac rehabilitation process for a period of 12 weeks. During this process, the patients will be chosen on a random basis to receive placebo inhalation solution or AIR001. The purpose of this study is to calculate how a patient’s capacity to exercise changes during peak oxygen consumption.
Mast’s investigational new drugs
The company is undergoing investigational clinical stage studies for two new drugs, vepoloxamer and AIR001. The latter one is in Phase 2 clinical development. This will be the most important bet for the company; especially after crashed drug trial of Vepoloxamer, which was earlier, the company’s lead product.
In what may be called a bet to bounce back, AIR001 is one of the most important products for Mast Therapeutics Inc, and will be able to regain the respect with it. At present, the company has three Phase 2 studies where patients are enrolled to check AIR001.